Caroline Demangel trained in the National Institute of Agronomy Paris-Grignon (AgroParisTech). After a PhD in Biotechnology in the Bertin company (Plaisir, France), she opted for a career in academic research. She did a post-doc in the Centenary Institute (Sydney, Australia), designing and testing anti-tuberculous vaccines that target dendritic cells in Warwick Britton’s Lab. Back in Paris in 2002, she joined the team of Stewart Cole at the Institut Pasteur to develop novel approaches to mycobacterial disease diagnosis and treatment, with a particular focus on Leprosy and Buruli ulcer disease. Since 2011, she’s been directing the “Immunobiology and Infection” Unit in the Immunology Department of the Pasteur Institute. Her team studies the mechanisms by which pathogenic mycobacteria establish chronic infections in humans, in particular the bacterial virulence factors interfering with host immunity. The aim of these studies is to find innovative approaches to better treat mycobacterial infections, and identify novel natural compounds with immunomodulatory potential.
Therapeutic potential of mycolactone surrogates
Inflammation adversely affects the health of millions of people worldwide and there is an unmet medical need for better anti-inflammatory drugs. Our group evaluates the therapeutic interest of mycolactone, a polyketide-derived macrolide produced by […]
Mycolactone of M. ulcerans and immunodulation
Mycolactone is a diffusible macrolide produced by Mycobacterium ulcerans, the causative agent of a chronic skin disease called Buruli ulcer. Defective cellular immune responses, at the local and systemic levels, are hallmarks of Buruli […]
Biomarkers of Buruli ulcer disease
Buruli ulcer is the third most common mycobacterial disease after Tuberculosis and Leprosy. It is a chronic, necrotizing disease of the skin and soft tissues that is reported in over thirty tropical and subtropical […]
Mycobacterial phenolic glycolipids and innate host defenses
Across different species of mycobacteria, phenolic glycolipids (PGL) share a common lipid core and phenol ring that are embedded in the cell envelope, and differ in the saccharidic portion that is exposed on the […]
Mycolactone of M. ulcerans and the actin cytoskeleton
A distinctive feature of the human pathogen Mycobacterium ulcerans is the production of mycolactone. This original polyketide-derived macrolide is essential for bacterial virulence and sufficient to induce ulcerative lesions in the skin that are […]
2019A comprehensive assessment of demographic, environmental, and host genetic associations with gut microbiome diversity in healthy individuals, Microbiome 2019 Sep;7(1):130.
2019Recombinant Antibodies against Mycolactone, Toxins (Basel) 2019 Jun;11(6).
2019Ipomoeassin F Binds Sec61α to Inhibit Protein Translocation, J. Am. Chem. Soc. 2019 May;.
2018Sec61 blockade by mycolactone: A central mechanism in Buruli ulcer disease, Biol. Cell 2018 Jul;.
2018Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines, Genome Med 2018 07;10(1):59.
2018Proteomics reveals scope of mycolactone-mediated Sec61 blockade and distinctive stress signature, Mol. Cell Proteomics 2018 Jun;.
2018Mycobacterial Phenolic Glycolipids Selectively Disable TRIF-Dependent TLR4 Signaling in Macrophages, Front Immunol 2018;9:2.
2017Mycolactone displays anti-inflammatory effects on the nervous system, PLoS Negl Trop Dis 2017 Nov;11(11):e0006058.
2017Modular total syntheses of mycolactone A/B and its [(2)H]-isotopologue, Org. Biomol. Chem. 2017 Sep;15(36):7518-7522.
2017Sec61 blockade by mycolactone inhibits antigen cross-presentation independently of endosome-to-cytosol export, Proc. Natl. Acad. Sci. U.S.A. 2017 Jul;114(29):E5910-E5919.
+View full list of publications